Status:

ACTIVE_NOT_RECRUITING

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

Lead Sponsor:

Sol-Gel Technologies, Ltd.

Conditions:

Gorlin Syndrome

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patideg...

Detailed Description

This is a global, multicenter, randomized, double-blind, stratified, vehicle-controlled study of the efficacy and safety of Patidegib Gel 2%, applied topically twice daily to the face of adult subject...

Eligibility Criteria

Inclusion

  • Key
  • The subject must be at least 18 years old at the Screening Visit.
  • The subject must be confirmed to have a PTCH1 mutation.
  • The subject must have at least 10 BCCs on the face at Randomization (Baseline/Day 1).
  • The subject must be willing to abstain from application of any non-study topical medication (prescription or over the counter) to their facial skin for the duration of the trial, except as prescribed by the investigator.
  • Key

Exclusion

  • The subject has used topical treatment to the face or systemic therapies that might interfere with the evaluation of the study Investigational Product (IP).
  • The subject is known to have hypersensitivity to any of the ingredients in the IP formulation.
  • The subject has uncontrolled systemic disease.
  • The subject has been treated for invasive cancer within the past 5 years excluding chronic lymphocytic leukemia Stage 0, non-melanoma skin cancer, successfully treated melanoma in situ and Stage I melanoma, Stage I cervical cancer, or ductal carcinoma in situ of the breast.
  • Inefficacy of previous Hedgehog inhibitor therapy.

Key Trial Info

Start Date :

March 17 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 1 2026

Estimated Enrollment :

140 Patients enrolled

Trial Details

Trial ID

NCT06050122

Start Date

March 17 2024

End Date

August 1 2026

Last Update

October 14 2025

Active Locations (40)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 10 (40 locations)

1

Northwest Arkansas Clinical Trials Center

Rogers, Arkansas, United States, 72758

2

Center for Dermatology Clinical Research

Fremont, California, United States, 94538

3

University of California Los Angeles (UCLA) - Center for Inflammatory Bowel Diseases - Westwood Location

Los Angeles, California, United States, 90024

4

The Dermatology Center of Newport

Newport Beach, California, United States, 92660